EUVIMEDEUVIMED entdecken
Crossref

Virtual platelet cross‐matching as transfusion management for patients with immune platelet refractoriness

Carolina Bonet-Bub iD, Bruna Paccola Blanco, Thais Carvalho de Oliveira, Tamiris Baptista Sampaio, Itala Gomes, Valeria de Freitas Dutra, Thiago Henrique Costa, José Mauro Kutner

Vox Sanguinis · 2024

DOI: 10.1111/vox.13565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Carolina Bonet-Bub und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Israelita Albert Einstein, São Paulo, Brazil. Hauptthemen laut MEDLINE: Blood Platelets, Thrombocytopenia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives This study describes the use of the Epvix platform for virtual cross‐matching (VC) of human leucocyte antigen (HLA)‐compatible platelets for patients with immune platelet refractoriness, and demonstrates effectiveness of the selected platelets. Materials and Methods A prospective cohort of haematological patients was evaluated from 2018 to 2022. HLA‐typed donor bank profile was previously uploaded to the Epvix platform. Each patient's antibody reactivity panel (PRA) was included in the platform. Then, search, selection and VC were performed, and 24‐h‐corrected count increment (CCI) platelet transfusion was calculated (reference ≥2500).

Results

Six patients were included (four female, two male), with mean age of 61 years. HLA antibodies were detected as the cause of immunity for all patients, whereas four patients also had non‐immune causes. High percentage of alloimmunization was detected in all studied patients (mean PRA: 85.7%). Thirty different donors were able to schedule and perform platelet donations. The mean 24‐h CCI count was 9882. All platelet transfusions achieved a satisfactory CCI count except for two transfusion events. Presence of non‐immune causes identified in these two cases could account for the unsatisfactory CCI.

Conclusion

Epvix is a free application hosted on the Web and uses the HLAMatchmaker algorithm to generate histocompatibility reports. This study demonstrates the efficiency of VC performed by Epvix. However, physical cross‐matching will still be necessary in some instances, as the platform does not support human platelet antigen polymorphism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PlateletsThrombocytopeniaHumansMaleFemaleMiddle AgedProspective StudiesBlood TransfusionPlatelet TransfusionHLA AntigensHistocompatibility Antigens Class I

Stichwörter der Autor:innen

HLA antibodiesepletsimmune platelet refractorinessplatelet transfusion

Substanzen

HLA AntigensHistocompatibility Antigens Class I

Autor:innen und Institutionen

  • Hospital Israelita Albert Einstein, São Paulo, Brazil.

ORCID-Profile: Carolina Bonet-Bub

Zitieren

APA

Bonet-Bub, C., Blanco, B. P., de Oliveira, T. C., Sampaio, T. B., Gomes, I., de Freitas Dutra, V., Costa, T. H., & Kutner, J. M. (2024). Virtual platelet cross‐matching as transfusion management for patients with immune platelet refractoriness. Vox Sanguinis. https://doi.org/10.1111/vox.13565

Vancouver

Bonet-Bub C, Blanco BP, de Oliveira TC, Sampaio TB, Gomes I, de Freitas Dutra V, et al. Virtual platelet cross‐matching as transfusion management for patients with immune platelet refractoriness. Vox Sanguinis. 2024. doi:10.1111/vox.13565

BibTeX
@article{BonetBub2024,
  author = {Bonet-Bub, Carolina and Blanco, Bruna Paccola and de Oliveira, Thais Carvalho and Sampaio, Tamiris Baptista and Gomes, Itala and de Freitas Dutra, Valeria and Costa, Thiago Henrique and Kutner, José Mauro},
  title = {Virtual platelet cross‐matching as transfusion management for patients with immune platelet refractoriness},
  journal = {Vox Sanguinis},
  year = {2024},
  doi = {10.1111/vox.13565}
}
Kostenlos starten →